# Urinary Biomarker Study With Sulindac and Difluoromethylornithine

> **NCT01636128** · PHASE2 · WITHDRAWN · sponsor: **Cancer Prevention Pharmaceuticals, Inc.**

## Conditions studied

- Focus of Study: Drug Response Biomarkers, Chemoprevention, Neoplasms

## Interventions

- **DRUG:** difluoromethylornithine
- **DRUG:** Sulindac

## Key facts

- **NCT ID:** NCT01636128
- **Lead sponsor:** Cancer Prevention Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-03
- **Primary completion:** 2016-03
- **Final completion:** 2016-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Funding and staffing
- **Last updated:** 2014-07-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01636128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01636128, "Urinary Biomarker Study With Sulindac and Difluoromethylornithine". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01636128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*